Avalon GloboCare and its Subsidiary Genexosome Technologies Announce Discovery and Development of World's First Saliva-Based Exosomal Biomarker "miR-185" as Dual Diagnostic and Therapeutic Target for Oral Cancer

Stock Information for Avalon GloboCare Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Avalon GloboCare Corp.

Avalon GloboCare Advances Next Generation Cellular Immunotherapy with FLASH-CAR(TM) Technology for Blood Cancers
Avalon GloboCare Partners with HydroPeptide, a Leader in Epigenetics Skin Care, to Accelerate Regenerative ACTEX(TM) Product Development and Commercialization
Avalon GloboCare Achieves Major Milestones Advancing Immunotherapeutic Program towards Combatting Cytokine Storm Associated with COVID-19 Lung Damage and Mortality
Avalon GloboCare to Present at the 32nd Annual ROTH Conference on March 16, 2020
Avalon GloboCare CEO David Jin, M.D., Ph.D. to Co-Chair the "Cellular Therapy in the Asia Pacific Region" Session at the Annual Meetings of the Transplantation and Cellular Therapy (TCT) -- ASTCT and CIBMTR Tandem Meeting 2020
Avalon GloboCare to Present at Biotech Showcase(TM) 2020
Avalon GloboCare Partners with China (Nanjing) Cell Valley to Advance Cellular Medicines
Avalon GloboCare to Present at the 12th Annual LD Micro Main Event on December 10th

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.